Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Cytarabine 4fludarabine phosphate 3fludarabine 3Methotrexate 3merphos 2Pentetic Acid 2Methylprednisolone 2Hydrocortisone 2Cyclophosphamide 2Biopsy 2revumenib 1pegaspargase 1ixazomib 1hydrocortisone hemisuccinate 1ethanolamine oleate 1asparaginase erwinia chrysanthemi recombinant 1X-Rays 1Whole-Body Irradiation 1Vincristine 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Sulfamethoxazole 1Stem Cell Transplantation 1Specimen Handling 1Sodium Chloride 1Sirolimus 1Saline Solution, Hypertonic 1Saline Solution 1Radiotherapy 1Psychiatric Rehabilitation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Biphenotypic, Acute × Liposomes × Clear all
NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Children's Oncology Group

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡